Cardiologists’ Anger Flares Anew Over ABIM Maintenance of Certification
(UPDATED) Frustration over MOC is nothing new, but alternative certification options and a fresh, post-COVID perspective are fueling the fire.
Related Articles
Oral GLP-1 Drug Yields 12% Weight Loss in Nondiabetic Patients With Obesity
ATTAIN-1 is the second trial this year to show positive results with once-daily orforglipron, with best results seen at the top dose.
Stroke Protection Holds Up Long-term After LAA Closure: NCDR/Medicare Data
Yet 44% of the high-risk patients, from LAAO’s early era, died by 5 years—researchers say this knowledge can aid decision-making.
Insights on Intrepid 2-Yr Mitral TF EFS
Gilbert Tang, MD Mount Sinai Health System New York, NY Firas Zahr, MD Oregon Health & Science University Portland, OR Forgot Your Password? Enter the…
New ACC/AHA Hypertension Guidelines Still Urge Early Treatment but With Some Twists
The document, last updated in 2017, promotes use of the PREVENT calculator as well as more flexible BP goals.
Beyond the Data: Digital Innovation in Mexico
Mamas Mamas sits down with Sergio Dominguez Miranda for an overview on the use of digital twins to predict patient outcomes.
Coronary Sinus Reducer ‘Promising’ for Refractory Angina: Meta-analysis
Effects are more modest in placebo-controlled versus nonrandomized studies, with experts calling for further research.
New ACC/AHA Hypertension Guidelines Still Urge Early Treatment but With Some Twists
The document, last updated in 2017, promotes use of the PREVENT calculator as well as more flexible BP goals.
For Monotherapy, P2Y12 Inhibitor Bests Aspirin After PCI for ACS: Meta-analysis
The study can’t supplant an RCT in this space, but does provide clear support for both short DAPT and P2Y12 inhibitors post-ACS.
Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol
The drug could be an option for patients who are unable to tolerate statins, or unwilling to take them.
The Global Burden of Degenerative Mitral Valve Disease: Part 2
Continuing the conversation, Juan Granada hears about Guido Ascione’s recent presentation on the global burden of degenerative mitral valve disease at NY Valves 2025.